Results 121 to 130 of about 348 (143)
Some of the next articles are maybe not open access.
Expert Review of Ophthalmology, 2010
The mast cell-stabilizer–antihistamine class of medications has become physicians’ first choice for treating seasonal allergic conjunctivitis owing to the rapid onset of action, long duration of effect and improved comfort. Bepotastine besilate ophthalmic solution 1.5% (Bepreve™, ISTA Pharmaceuticals, Inc., CA, USA) has recently been approved by the US
Gregg J Berdy, Heather S Oliff
openaire +1 more source
The mast cell-stabilizer–antihistamine class of medications has become physicians’ first choice for treating seasonal allergic conjunctivitis owing to the rapid onset of action, long duration of effect and improved comfort. Bepotastine besilate ophthalmic solution 1.5% (Bepreve™, ISTA Pharmaceuticals, Inc., CA, USA) has recently been approved by the US
Gregg J Berdy, Heather S Oliff
openaire +1 more source
Efficacy and Safety of Bepotastine Besilate in the Treatment of Chronic Urticaria
Nishi Nihon Hifuka, 2006Minao FURUMURA +2 more
openaire +1 more source